Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

71.21
1,484,211

-0.73 (-1.01%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $71.19 -0.02 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Sustained momentum with respect to inpatient dialysis revenue per treatment is likely to have aided DaVita's (DVA) top line in the fourth quarter despite the ongoing pandemic-led business challenges.

Cardiovascular Systems' (CSII) Q2 Earnings Lag Estimates

by Zacks Equity Research

Cardiovascular Systems (CSII) exhibits a robust performance by its worldwide coronary franchise despite challenging business climate.

DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

Doximity (DOCS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Doximity's (DOCS) fiscal third-quarter results are likely to reflect growth in its telehealth platform and robust net revenue retention rate.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.

Bio-Rad (BIO) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) Q4 top line.

Medtronic (MDT) Cardiovascular Line Rebounds, Spine Stays Soft

by Zacks Equity Research

Medtronic (MDT) is registering organic growth in the Cardiovascular, Neuroscience and Diabetes segments.

LabCorp (LH) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

LabCorp's (LH) Covance Drug Development Q4 results are expected to reflect an increase in organic revenues on base business growth and contribution from COVID testing performed through the central lab.

Hologic (HOLX) Q1 Earnings Surpass Estimates, Margins Down

by Zacks Equity Research

Impressive performance by Hologic's (HOLX) Breast Imaging and Interventional Breast Solutions drove Q1 revenues.

What's in Store for Canopy Growth (CGC) in Q3 Earnings?

by Zacks Equity Research

New product launches across the CBD product portfolio and robust demand for legal cannabis products are likely to drive Canopy Growth's (CGC) Q3 top line.

Quest Diagnostics (DGX) Q4 Revenues Top Estimates, Margins Down

by Zacks Equity Research

Quest Diagnostics' (DGX) base business revenues grew year over year, achieving record levels in the fourth quarter.

Align Technology (ALGN) Q4 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Robust segmental growth and iTero sales are driving Align Technology's (ALGN) Q4 top line.

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its progress in the WAVE study and a strong product portfolio.

Thermo Fisher (TMO) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Thermo Fisher's (TMO) Q4 earnings surpassed the Zacks Consensus Estimate with strength across the Analytical Instruments segment driving the top line.

IDEXX (IDXX) Q4 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Growth in CAG Diagnostics revenues and CAG Diagnostics capital instrument revenues drove IDEXX (IDXX) Q4 revenues.

Here's Why You Should Retain Edwards Lifesciences (EW) Stock

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW) on continued strong adoption of the SAPIEN 3 Ultra platform and the PASCAL system.

Can Henry Schein (HSIC) Keep the Earnings Surprise Streak Alive?

by Zacks Equity Research

Henry Schein (HSIC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum on the back of strength in the Proprietary Products business. However, forex woes persist.

CVS Health (CVS) Q4 Earnings to Gain From COVID Vaccine Sales

by Zacks Equity Research

CVS Health (CVS) is expected to have seen a significant part of its specialty orders being placed digitally through Q4 months, with growth drivers being COVID testing, vaccines and omni-channel.

Cardinal Health (CAH) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Cardinal Health's (CAH) fiscal second-quarter results are likely to reflect solid performance in the Pharmaceutical segment.

Diagnostics Sales to Drive Hologic's (HOLX) Q1 Earnings

by Zacks Equity Research

Strength in the Diagnostics division is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.

BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.

Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.

McKesson (MCK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet (ZBH) struggles to sustain the recovery trend in the second half of 2021.